Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Trigeminal Neuropathic Pain
Interventions: PET Scans, transcranial direct current stimulation (tDCS), MRI, sham tDCS (prior to real tDCS); Procedure · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: Sutezolid, Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Nonalcoholic Steatohepatitis
Interventions: MK-3655, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 48
States / cities: Tucson, Arizona • North Little Rock, Arkansas • Canoga Park, California + 37 more

Conditions: Intestinal Failure Associated Liver Disease
Interventions: NST-6179 Part A, NST-6179 Part B, Matched Placebo; Drug · Other
Lead sponsor: NorthSea Therapeutics B.V.; Industry
Eligibility: 16 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 13
States / cities: Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Down Syndrome
Interventions: Rivastigmine, Liquid Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 2,731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 72
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more

Conditions: Non-segmental Vitiligo
Interventions: VYN201 Gel, Vehicle Gel; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more

Conditions: Tendon Injuries
Interventions: GSK1278863, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Overweight
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 43
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more

Conditions: Prurigo Nodularis
Interventions: barzolvolimab, Matching Placebo; Biological · Other
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 30 more

Conditions: the Pharmacokinetic Profile of Icariin in Humans
Interventions: Icariin, Matching placebo; Drug · Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Dapagliflozin, Metformin IR, Placebo matching with Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 34
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 26 more

Conditions: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Plecanatide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 155
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 142 more

Conditions: Posttraumatic Stress Disorder
Interventions: Pregnenolone, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: H3 K27M, Glioma
Interventions: Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 67
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more

Conditions: Episodic Migraine
Interventions: Dextromethorphan and quinidine, Placebo; Drug
Lead sponsor: Cady, Roger, M.D.; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more

Conditions: Generalized Anxiety Disorder
Interventions: SEP-363856, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Tucson, Arizona • Encino, California • Sherman Oaks, California + 13 more

Conditions: Postural Orthostatic Tachycardia Syndrome (POTS)
Interventions: REGN7544, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 15
States / cities: Gilbert, Arizona • Carlsbad, California • Palo Alto, California + 12 more

Conditions: Osteoarthritis, Knee
Interventions: Vitamin D (cholecalciferol), Placebo; Dietary Supplement
Lead sponsor: Tufts Medical Center; Other
Eligibility: 45 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions: LV305, G305, LV305-matching placebo, G305-matching placebo; Biological · Other
Lead sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Stroke
Interventions: SUN13837, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Mobile, Alabama • Encinita, California • Oceanside, California + 29 more

Conditions: Essential Tremor
Interventions: CBD/THC, Placebo oral capsule; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Thrombotic Microangiopathy
Interventions: Ravulizumab, Placebo, Best supportive care; Biological · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Tampa, Florida • Grosse Pointe Farms, Michigan • Durham, North Carolina + 2 more

Search by objective public record fields.

Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Rivastigmine Study in Adolescents With Down Syndrome

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Icariin to Prevent Corticosteroid-related Memory Changes

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)

Neurosteroids for Treatment of PTSD in Veterans

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Vitamin D to Slow Progression of Knee Osteoarthritis

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke

Trial of Cannabis for Essential Tremor

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant